LBT Innovations Ltd (ASX: LBT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
LBT Innovations Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$29.87 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.75 billion
Earnings per share
-0.045
Dividend per share
N/A
Year To Date Return
27.27%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
LBT Innovations Ltd (ASX: LBT)
Latest News
Healthcare Shares
Guess which small cap ASX stock is rocketing 80% today
Healthcare Shares
Guess which ASX AI stock rocketed 170% on an AstraZeneca update
Healthcare Shares
LBT Innovations (ASX:LBT) share price plummets 14% despite positive update
Healthcare Shares
Why the LBT Innovations share price is charging higher today
Speculative
Why the LBT Innovations share price rocketed 243% higher on Tuesday
⏸️ Investing
3 fast-growing biotech shares at the top of my watch list
⏸️ Investing
Here's why LBT Innovations Limited shares rocketed 89% today
⏸️ Investing
What investors can learn from LBT Innovations Limited's slump to a seven-month low
⏸️ Investing
4 stocks that soared more than 16% today
LBT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About LBT Innovations Ltd
LBT Innovations Ltd is a designer of technology solutions for the medical industry. Its first product, MicroStreak, in the automation of the culture plate streaking process. Its second product, the Automated Plate Assessment System(APAS) is based upon LBT's intelligent imaging and machine learning software and remains the only U.S. FDA-cleared artificial intelligence technology for automated imaging, analysis, and interpretation of microbiology culture plates following incubation. The company operates in Australia, U.S., Sweden, UK, and Germany.
LBT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Nov 2024 | $0.02 | $0.00 | 0.00% | 1,557,438 | $0.02 | $0.02 | $0.02 |
| 12 Nov 2024 | $0.02 | $0.00 | 0.00% | 1,395,516 | $0.02 | $0.02 | $0.02 |
| 11 Nov 2024 | $0.02 | $0.00 | 0.00% | 60,750 | $0.02 | $0.02 | $0.02 |
| 08 Nov 2024 | $0.02 | $0.00 | 0.00% | 230,000 | $0.02 | $0.02 | $0.02 |
| 07 Nov 2024 | $0.02 | $0.00 | 0.00% | 187,191 | $0.01 | $0.02 | $0.01 |
| 06 Nov 2024 | $0.02 | $0.00 | 0.00% | 300,000 | $0.02 | $0.02 | $0.02 |
| 05 Nov 2024 | $0.02 | $0.00 | 0.00% | 2,404,981 | $0.02 | $0.02 | $0.02 |
| 04 Nov 2024 | $0.02 | $0.00 | 0.00% | 551,646 | $0.02 | $0.02 | $0.02 |
| 01 Nov 2024 | $0.01 | $0.00 | 0.00% | 881,633 | $0.01 | $0.02 | $0.01 |
| 31 Oct 2024 | $0.02 | $0.00 | 0.00% | 780,017 | $0.02 | $0.02 | $0.02 |
| 30 Oct 2024 | $0.02 | $0.00 | 0.00% | 308,305 | $0.02 | $0.02 | $0.02 |
| 29 Oct 2024 | $0.02 | $0.00 | 0.00% | 720,208 | $0.02 | $0.02 | $0.02 |
| 28 Oct 2024 | $0.01 | $0.00 | 0.00% | 1,505,747 | $0.02 | $0.02 | $0.01 |
| 25 Oct 2024 | $0.02 | $0.00 | 0.00% | 1,128,833 | $0.02 | $0.02 | $0.01 |
| 24 Oct 2024 | $0.01 | $0.00 | 0.00% | 2,091,084 | $0.01 | $0.01 | $0.01 |
| 23 Oct 2024 | $0.02 | $0.00 | 0.00% | 4,478,872 | $0.02 | $0.02 | $0.02 |
| 22 Oct 2024 | $0.02 | $0.00 | 0.00% | 1,035,000 | $0.02 | $0.02 | $0.02 |
| 21 Oct 2024 | $0.02 | $0.00 | 0.00% | 1,614,007 | $0.02 | $0.02 | $0.02 |
| 18 Oct 2024 | $0.02 | $0.00 | 0.00% | 1,976,250 | $0.02 | $0.02 | $0.02 |
| 17 Oct 2024 | $0.02 | $0.00 | 0.00% | 1,528,634 | $0.02 | $0.02 | $0.02 |
| 16 Oct 2024 | $0.02 | $0.00 | 0.00% | 2,032,204 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 11 Sep 2024 | Brenton Barnes | Exercise | 2,000,000 | $10,000 |
Exercise of options.
|
| 11 Sep 2024 | Brenton Barnes | Buy | 2,000,000 | $10,000 |
Exercise of options.
|
| 16 Aug 2024 | Brenton Barnes | Sell | 7,439,441 | $124,208 |
On-market trade.
|
| 16 Aug 2024 | Brenton Barnes | Exercise | 33,000,000 | $165,000 |
Exercise of options.
|
| 16 Aug 2024 | Brenton Barnes | Buy | 25,000,000 | $125,000 |
Exercise of options.
|
| 16 Aug 2024 | Brenton Barnes | Buy | 8,000,000 | $40,000 |
Exercise of options.
|
| 27 Jun 2024 | Rebecca Wilson | Buy | 6,798,700 | $33,993 |
Exercise of options.
|
| 27 Jun 2024 | Rebecca Wilson | Exercise | 6,798,700 | $33,993 |
Exercise of options.
|
| 19 Dec 2023 | Brian O'Dwyer | Issued | 524,379 | $31,500 |
Director remuneration. VWAP
|
| 19 Dec 2023 | Rebecca Wilson | Issued | 1,250,000 | $15,000 |
Director remuneration.
|
| 19 Dec 2023 | Brenton Barnes | Issued | 1,031,250 | $24,750 |
Director remuneration. VWAP
|
| 15 Nov 2023 | Brenton Barnes | Issued | 70,000,000 | $280,000 |
Rights issue.
|
| 15 Nov 2023 | Brenton Barnes | Issued | 20,000,000 | $100,000 |
Rights issue.
|
| 15 Nov 2023 | Brenton Barnes | Issued | 50,000,000 | $250,000 |
Rights issue.
|
| 15 Nov 2023 | Damian Lismore | Transfer | 539,494 | $2,157 |
Off-market transfer. Assuming off - market transfer of shares
|
| 15 Nov 2023 | Damian Lismore | Transfer | 539,494 | $2,157 |
Off-market transfer. Assuming off - market transfer of shares
|
| 15 Nov 2023 | Damian Lismore | Issued | 4,160,000 | $20,800 |
Rights issue.
|
| 15 Nov 2023 | Damian Lismore | Issued | 4,160,000 | $16,640 |
Rights issue. There is typo error for post holding
|
| 15 Nov 2023 | Rebecca Wilson | Issued | 13,597,400 | $67,987 |
Rights issue.
|
| 15 Nov 2023 | Rebecca Wilson | Issued | 13,597,400 | $54,389 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Rebecca Wilson | Non-Executive Director | Jul 2023 |
Ms Wilson is an experienced company director with private, ASX listed and not-for-profit organisations and has significant experience leading companies in important commercial activation phases working with CEOs as both an advisor and Non-executive Director to develop and execute effective business strategies that supports accelerated and sustained growth.
|
| Mr Brenton John Barnes | Chief Executive OfficerManaging Director | Aug 2016 |
Mr Barnes has been CEO & Managing Director since 2016, responsible for bringing the APAS machine vision technology through product development into commercialisation. The result is a patent protected platform technology that has been proven to automate culture plate reading more accurately than scientists and with improved quality and traceability of results.
|
| Mr Brian O'Dwyer | Non-Executive Director | Oct 2021 |
Mr O'Dwyer has more than 25 years of experience in the healthcare and laboratory testing industry. Brian brings industry knowledge and expertise in laboratory testing businesses to the Board. His experience spans across the establishment, management, integration and restructuring of both business and commercial operations through the clinical research spectrum.
|
| Mr Daniel (Dan) Hill | Non-Executive Director | Dec 2023 |
Mr Hill has a background working in finance, funds management and private equity. He is an experienced investor and business owner, with a track record of building successful businesses across a variety of industry sectors.
|
| Mr Ian Wisenberg | Non-Executive Director | Oct 2024 |
Mr Wisenberg has held C-suite leadership positions with global life science and pharmaceutical companies, as well as an advisor to the industry on growth strategies and M&A. In recent years he led the acquisition of Bridgewest Groups first biologics manufacturing facility and operation from Pfizer in Adelaide, Australia. After the closing of the transaction, he was appointed Chief Executive Officer of the operating entity, BioCina Pty Ltd. Mr Wisenberg has an global network of pharmaceutical and large biotechnology companies with that includes specific relationships in drug manufacturing.
|
| Mr Ray Ridge | Chief Financial OfficerCompany Secretary | Feb 2020 |
-
|
| Ray Ridge | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Unicore Investments Pty Ltd | 223,190,000 | 13.79% |
| Viking Bcm Pty Ltd | 212,665,188 | 13.14% |
| Mr Brenton Barnes | 70,000,000 | 4.32% |
| Fabian Wisplinghoff | 65,690,100 | 4.06% |
| Hilmar Wisplinghoff | 65,690,100 | 4.06% |
| B Moran Pty Ltd | 56,414,858 | 3.49% |
| Jatayco Nominees Pty Ltd <Green Sf A/C> | 53,452,562 | 3.30% |
| Spiceme Capital Pty Ltd | 42,794,034 | 2.64% |
| Mr Mark Frank Capolupo | 32,500,000 | 2.01% |
| Hettich Holding Beteiligungs-Und Verwaltungs-Gmbh\C | 30,660,377 | 1.89% |
| Hawkeye Smsf Pty Ltd | 28,000,000 | 1.73% |
| Chag Pty Ltd | 28,000,000 | 1.73% |
| Mr Robert Andrew Finder | 25,947,542 | 1.60% |
| Bearay Pty Ltd <Brian Clayton S/F A/C> | 25,014,731 | 1.55% |
| Mr Raymond Robert Ridge <Ridge Family A/C> | 20,877,089 | 1.29% |
| Parker And Wilson Investments Pty Ltd <Parker And Wilson S/Fund A/C> | 20,396,100 | 1.26% |
| KEW Superannuation Fund Pty Ltd <K W Superannuation Fund A/C> | 17,424,000 | 1.08% |
| RJE Aerospace Pty Ltd <Equid Super A/C> | 16,117,366 | 1.00% |
| Christopher Jordan Shopov and Christopher James Shopov <Helter Skelter A/C> | 14,400,000 | 0.89% |
| Mrs Catherine Mary Costello | 13,290,272 | 0.82% |
